ILEX oncology acquires CD52 diagnostic rights for Campath.
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD / Q000032:analysis* / Q000276:immunology; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000276:immunology; D000074301:CD52 Antigen; D004345:Drug Industry; D006023:Glycoproteins / Q000032:analysis* / Q000276:immunology; D006801:Humans; D007938:Leukemia / Q000175:diagnosis* / Q000276:immunology; D008223:Lymphoma / Q000175:diagnosis* / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab